Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Articles online first > Minerva Urologica e Nefrologica 2020 Apr 16

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Urologica e Nefrologica 2020 Apr 16

DOI: 10.23736/S0393-2249.20.03683-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Androgen deprivation therapy prescription, blood and bone-density testing in a French population-based study exploring adherence to the French prostate cancer guidelines

Lucie-Marie SCAILTEUX 1, 2 , Frédéric BALUSSON 2, Emmanuel OGER 1, 2, Sébastien VINCENDEAU 3, Romain MATHIEU 3, 4

1 Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Department of Clinical Pharmacology, Rennes University Hospital, Rennes, France; 2 Université Rennes, EA 7449 REPERES ‘Pharmacoepidemiology and Health Services Research’, Rennes, France; 3 Urology Department, Rennes University Hospital, Rennes, France; 4 Université Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) Rennes, France


PDF


The safety profile of androgen deprivation therapy (ADT) is well known, and cardiovascular and osteoporosis risk factors should be assessed before ADT initiation. In order to examine whether the French Committee of Urologic Oncology prostate cancer (PCa) guidelines were properly followed by clinicians, including urologists, oncologists and radiotherapists, we used a nationwide comprehensive cohort of prostate cancer patients, who were new ADT users in 2011 and were followed up to 2013. Reimbursements for biological examinations and prescribers were identified, as well as PCa specialist consultations at drug initiation. Our results in this French cohort showed that the proportions of patients resorting to specialised care between one year and 3 months before ADT initiation and in the 6 months following was around 40 % for fasting glucose and 30 % for lipid assessments. Bone densitometry was performed on around 1% of patients. In the 12 months after ADT initiation, 75% of the patients were seen by a urologist and around 47% by an oncologist or a radiotherapist. Overall, there is still room for improvement in terms of ADT monitoring by clinicians and in the information provided to general practitioners and patients regarding the expected adverse effects of this treatment.


KEY WORDS: Prostate cancer; Population based-study; Blood testing; Bone-density testing; Safety

top of page